AbbVie Inc.

New York Stock Exchange
Back to all articles
Very Bullish +78

3 Major Reasons for Investors to Buy AbbVie Stock Before July 31st

📈 AbbVie trades at a forward P/E of 18x with a PEG ratio of 0.43 and a beta of 0.28, indicating low volatility relative to the broader market.

💰 The quarterly dividend was raised 5.5% to $1.73 per share, resulting in an annualized yield of 2.62%.

🚀 Skyrizi and Rinvoq combined generated $6.6 billion in Q1 revenue, with Skyrizi alone reaching $4.48 billion.

📊 Management raised full-year EPS guidance to a range of $14.08 to $14.28 ahead of the July 31 earnings report.

🔬 Skyrizi sales grew 30.9% year-over-year while Rinvoq sales increased 23.3% in the first quarter.

🛡️ The company has successfully transitioned away from Humira, with new drugs projected to generate nearly $32 billion annually.

📉 AbbVie delivered a 164% five-year return, significantly outperforming Pfizer's negative 23% return over the same period.

🏆 Wall Street consensus target price is set at $267.79 with 16 Buy and 8 Strong Buy ratings from analysts.

⚖️ AbbVie offers a combination of income, growth, and low volatility compared to peers facing patent cliffs or biosimilar erosion.

Bullish Signals
  • AbbVie trades at a PEG ratio of 0.43, suggesting the stock is undervalued relative to its earnings growth rate.
  • The company raised its quarterly dividend by 5.5% to $1.73, signaling strong cash flow and commitment to shareholder returns.
  • Skyrizi and Rinvoq combined generated $6.6 billion in Q1 revenue, demonstrating robust demand for the new growth engines.
  • Management raised full-year guidance for both Skyrizi ($21.6B) and Rinvoq ($10.2B), indicating confidence in future sales.
  • AbbVie achieved a 164% five-year gain, vastly outperforming competitor Pfizer which saw a -23% return over the same period.
  • The stock has a low beta of 0.28, providing downside protection and lower volatility compared to the S&P 500 average.
  • Analyst consensus target price of $267.79 is slightly above the current trading price of $265.52, reflecting positive sentiment.
  • AbbVie has successfully navigated the biosimilar valley that Merck is currently facing with its Keytruda franchise.
Full Analysis
AbbVie (NYSE: ABBV) is highlighted as a compelling investment opportunity ahead of its July 31 Q2 earnings report, driven by strong financial metrics and successful product transitions. The company trades at a forward P/E of 18x with a PEG ratio of 0.43 and a low beta of 0.28, offering a 2.62% dividend yield that recently increased by 5.5% to $1.73 per share. The core growth strategy relies on the blockbuster immunology drugs Skyrizi and Rinvoq, which combined generated $6.6 billion in Q1 revenue. Skyrizi sales reached $4.48 billion (up 30.9% YoY) while Rinvoq added $2.12 billion (up 23.3%), effectively replacing the declining Humira franchise. Management has raised full-year guidance for both drugs, projecting nearly $32 billion in combined annual sales. AbbVie's financial performance significantly outpaces peers like Pfizer and Merck over the last five years, with a 164% gain compared to Pfizer's decline. The company successfully navigated the biosimilar competition that threatens Merck's Keytruda franchise, positioning itself as a leader in income generation and growth with low market volatility.